Centocor Ortho Biotech Inc. and Schering-Plough Corporation has announced that Health Canada has granted approval of Simponi (golimumab) as a once-monthly, subcutaneous therapy for the treatment of ...
PHILADELPHIA, Oct. 19 New long-term data from two pivotal, Phase 3 clinical trials showed that patients with active rheumatoid arthritis (RA) receiving SIMPONI (TM) (golimumab) every four weeks ...
SIMPONI (Golimumab) 50mg/0.5mL solution for SC inj from Centocor Ortho Biotech The FDA has approved Simponi (golimumab, from Centocor Ortho Biotech), a human monoclonal antibody, anti-tumor necrosis ...
Janssen Submits Applications Requesting Approval Of SIMPONI® In U.S. And Europe For Treatment Of Moderately To Severely Active Ulcerative Colitis HORSHAM, Pa. and LEIDEN, Netherlands, July 16, 2012 ...
UK patients with psoriatic arthritis are on the brink of gaining access to an additional treatment option on the National Health Service in England and Wales after cost regulator's waved through Merck ...
HORSHAM, Pa., Sept. 27 /PRNewswire/ -- Centocor Ortho Biotech Inc. announced today that it has submitted a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration ...
Janssen Biotech announced the submission of a Biologics License Application (BLA) to the FDA requesting approval of an investigational intravenous formulation of Simponi (golimumab) for the treatment ...
European regulators have given clearance to Johnson & Johnson/Schering-Plough’s Simponi for the treatment of three rheumatic conditions: rheumatoid arthritis; psoriatic arthritis; and ankylosing ...
MSD (Merck & Co., Inc.), a global healthcare leader working to help the world be well, announced that the European Commission approved Simponi (golimumab) for the treatment of adult patients with ...
Janssen Biotech Inc. has submitted a biologics license application to the Food and Drug Administration requesting approval of an intravenous formulation of Simponi for the treatment of adults with ...
LEIDEN, The Netherlands, Sept. 23, 2013 /PRNewswire/ -- Janssen Biologics B.V. ("Janssen") announced today that the European Commission has approved SIMPONI® (golimumab) for the treatment of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results